MedTrace Logo

Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT06824701 · Status: SUSPENDED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-04-06

No results posted yet for this study

Summary

The purpose of this clinical trial is to learn if the study drug Tazemetostat combined with Zanubrutinib and anti-CD20 monoclonal antibody is safe and effective in treating patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.

Conditions

  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Interventions

DRUG

Tazemetostat

Tazemetostat will be self-administered BID as an oral treatment on a 28-day cycle.

DRUG

Zanubrutinib

Zanubrutinib will be self-administered BID as an oral treatment on a 28-day cycle.

DRUG

Rituximab

Rituximab or a biosimilar will be administered intravenously per standard of care.

DRUG

Obinutuzumab

Obinutuzumab will be administered intravenously on days 1, 8, 15 of cycle 1 and then day 1 of cycles 2 to 12.

Sponsors & Collaborators

Principal Investigators

  • Narendranath Epperla, MD, MS, FACP · Huntsman Cancer Institute/ University of Utah

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-12
Primary Completion
2032-01-31
Completion
2033-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06824701 on ClinicalTrials.gov